not happy, page-13

copy as forwarded- my thought at present is we need to bring the same pressure to bare to the board as we did earlier.
copy of fill email- (posted under this subject title)-


what is Novogen up to!

Hi Kym,

this is a copy of an earlier email by a fellow shareholder, I am reiterating my concern in the same tone.

This last time this type of notice got momentum the board was embarrassed by the outcome.
Do the shareholders need to become more vocal to get attention.

I shall be interested in your reply.
Much appreciated
Mike

Hi Kym
To put the Cantrixil toxicology results on the company website and not accompany with an explained announcement to the markets is extraordinary at the least. Why? I have sent many emails to you regarding my concerns with the lack of markets announcements where one is warranted.
The broader market has no idea what Novogen are up to and this morning 4% in MC drop on such a huge milestone, from my interpretation of the Toxicology results, to clinical trials is upsetting at the least. Isn’t this at least worthy of notifying the ASX.???
Or are these non disclosure patterns to the wider market, noticed in the last 10 months, have a wider motive.??
If there is no motive can shareholders and interested investors have access to a “layman terms” (Market announcement) of the toxicology report and what this means to the company moving forward.
Cheers

Copy of original by fellow shareholder.